Results 81 to 90 of about 80,978 (300)
Implementation of guideline‐recommended medical therapy for patients with heart failure in Europe
ESC Heart Failure, Volume 12, Issue 2, Page 790-798, April 2025.Abstract Physicians' adherence to guideline‐recommended heart failure (HF) treatment remains suboptimal, especially regarding the target doses. In particular, there is evidence that non‐cardiologists are less compliant with HF guideline recommendations. This is likely to have a detrimental impact on patients' survival, readmissions and quality of life.
Maurizio Volterrani +11 more
wiley +1 more source
Interventional therapies for chronic heart failure: An overview of recent developments
ESC Heart Failure, Volume 12, Issue 2, Page 1081-1094, April 2025.Abstract Heart failure (HF), the final manifestation of most cardiovascular diseases, has become a major global health concern, affecting millions of individuals. Despite basic drug treatments, patients present with high morbidity and mortality rates. However, recent advancements in interventional therapy have shown promising results in improving the ...
Bingchen Guo +7 more
wiley +1 more source
CHRONIC HEART FAILURE IN RUSSIAN FEDERATION: WHAT DO WE KNOW AND WHAT TO DO
Российский кардиологический журнал, 2016 The analysis is presented, of the three epidemiologic studies (EPOCHA-CHF, EPOCHA-Hospital-CHF, EPOCHA-Decompensation-CHF). In 16 years, prevalence of chronic heart failure (CHF) in Russia increased from 4,9% (1998) to 10,2% (2014), p=0,01.
I. V. Fomin
doaj +1 more source
Health Science Reports, 2020 Background and aims Direct‐acting antiviral agents (DAAs) for hepatitis C virus (HCV) infection have resulted in high rates of sustained virologic response (SVR) following 8 to 24 weeks of treatment.
Eric Lawitz +10 more
doaj +1 more source
Hospital readmissions for decompensated cirrhosis [PDF]
Clinical Liver Disease, 2014 Preventable hospital readmissions are common among patients with decompensated cirrhosis. Not only are they harmful to patients, they also negatively impact the financial margin for hospitals and clinicians. In the future, advanced technology will likely be used to improve patient education and in‐home monitoring.10, 11 For now, however, clinicians can
openaire +3 more sources
ESC Heart Failure, Volume 12, Issue 2, Page 1194-1202, April 2025.Abstract Aims Cardiac decompensation in cardiorenal syndrome (CRS) results in systemic congestion usually treated with diuretics. When despite high doses of diuretics, response is poor, ultrafiltration (UF) appears to be a useful and safe technique.
Borja Guerrero Cervera +12 more
wiley +1 more source
Drugs in ContextAcute heart failure (HF) is associated with poor prognosis. After the acute event, there is a vulnerable period during which the patient has a marked risk of readmission or death.
José Antonio Magaña Serrano +12 more
doaj +1 more source
ESC Heart Failure, Volume 12, Issue 2, Page 1203-1216, April 2025.The 366 patients diagnosed with transthyretin amyloidosis cardiomyopathy (ATTR‐CM) were analyzed regarding their clinical characteristics in the first year after approval of tafamidis 61 mg for ATTR‐CM in Germany. Nearly two‐thirds of the patients were in an advanced disease stage and 64% met the key criteria of the “Transthyretin Amyloidosis ...
Richard J. Nies +23 more
wiley +1 more source
Treatment of an Adult with Skeletal Class III and A Hemimandibular Elongation A Multidisciplinary Approach [PDF]
Journal of Clinical and Diagnostic Research, 2016 Eshan Awasthi +4 more
doaj +1 more source